Lyka Labs Share Price Today

Lyka Labs standalone profit surges 159% in Q1FY27 on export strength

Lyka Labs’ Q1FY27 results show a significant profitability turnaround with standalone PAT up 159% to ₹210.03 lakh and consolidated PAT up 105% to ₹204.66 lakh. Export revenues surged 68%, driving growth, while domestic sales grew moderately. EBITDA margins compressed slightly due to higher finance costs and lower other income.

Lyka Labs Limited Passes All Five Resolutions at 47th Annual General Meeting

Lyka Labs Limited held its 47th AGM on 10th August 2026 via video conferencing, with all five ordinary resolutions passed by requisite majority through e-voting. Key approvals included adoption of audited financial statements for FY ended 31st March 2026, re-appointment of Mr. Shashil Philip Mendonsa as Director, ratification of cost auditor remuneration for FY 2025-2026 and FY 2026-2027, and approval of material related party transactions with IPCA Laboratories Limited for FY 2026-27. The total votes polled for Resolutions 1 through 4 stood at over 22 million, with approximately 99.99% in favour, while Resolution 5 recorded 1034655 votes in favour (99.84%) with promoters abstaining as interested parties.

Lyka Labs seeks approval for ₹75 crore IPCA transactions at AGM

Lyka Labs Limited has scheduled its 47th Annual General Meeting for August 10, 2026, via video conferencing. The meeting will seek shareholder approval for material related party transactions with promoter IPCA Laboratories Limited worth up to ₹75 crore for FY 2026-27. Additionally, shareholders will vote on the ratification of remuneration for the cost auditor and the adoption of audited financial statements for FY26.

Lyka Labs Annual Report FY2025-26: Consolidated Revenue Declines, Net Loss Widens on Exceptional Impairment Charge

Lyka Labs Limited filed its FY2025-26 Annual Report on 17th July, 2026, reporting a consolidated net loss of Rs. 1,057.96 Lakhs against a net profit of Rs. 811.41 Lakhs in FY25, on total consolidated revenue of Rs. 13,194.24 Lakhs versus Rs. 14,072.71 Lakhs. The standalone net loss of Rs. 3,243.24 Lakhs was significantly impacted by an exceptional impairment charge of Rs. 2,301.44 Lakhs on the company's subsidiary Lyka BDR International Limited. The NCLT-sanctioned merger of Lyka Exports Limited with the company became effective during the year, with 4,62,711 equity shares pending allotment to eligible shareholders. The 47th AGM is scheduled for 10th August, 2026, where shareholders will consider, among other items, approval of related party transactions with IPCA Laboratories Limited up to ₹75,00,00,000 for FY 2026-27.

Lyka Labs Limited announces 47th AGM on Aug 10

Lyka Labs Limited has announced its 47th Annual General Meeting for August 10, 2026, via video conferencing. The company filed disclosures with BSE and NSE regarding newspaper advertisements published in Financial Express and Loksatta-Jansatta to inform shareholders.

Lyka Labs promoter Kunal Gandhi increases stake to 9.85%

Promoter Kunal N. Gandhi of Lyka Labs Limited acquired 14,176 equity shares on June 29, 2026, increasing his stake to 9.85% from 9.81%. The shares were bought on the NSE and BSE for ₹10,28,414.16, complying with SEBI PIT Regulations.